General Information |
| Clinical trials phase |
Phase 1 |
| Start date (estimated) |
2021-02-18 |
| Clinical feature |
| Label |
breast cancer |
| Link |
http://purl.obolibrary.org/obo/DOID_1612 |
| Description |
An organ system cancer that originates in the mammary gland.; Xref MGI. OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=IRCT20200429047241N1 |
| Other study identifiers |
| Name |
IRCT20200429047241N1 |
| Description |
(IRCT registration number) |
|
| Source weblink |
http://en.irct.ir/trial/47603 |
| Regulatory body approval |
| Name |
Vice- Chancellor in Research Affairs-Tehran University of Medical Science |
| Country |
|
|
| Approval number |
IR.TUMS.VCR.REC.1398.232 |
| Sponsors |
International Center for Personalized Medicine (ICPM)
|
Cells |
| Which differentiated cell type is used |
| Label |
natural killer cell |
| Link |
http://purl.obolibrary.org/obo/CL_0000623 |
| Description |
A lymphocyte that can spontaneously kill a variety of target cells without prior antigenic activation via germline encoded activation receptors and also regulate immune responses via cytokine release and direct contact with other cells. |
|
Recruitment |
| Recruitment Status |
Not yet recruiting |
| Estimated number of participants |
32 |
